Powder: -20°C for 3 years
In solvent: -80°C for 2 years
(E/Z)-Zotiraciclib inhibits <a href="/target/CDK" style="display: inline; color: #c13a36">CDK</a>2, <a href="/target/JAK" style="display: inline; color: #c13a36">JAK</a>2, and <a href="/target/FLT" style="display: inline; color: #c13a36">FLT</a>3 effectively with IC50s of 13, 73, and 56 nM, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 66.00 | |
5 mg | In stock | $ 99.00 | |
10 mg | In stock | $ 139.00 | |
25 mg | In stock | $ 257.00 | |
50 mg | In stock | $ 399.00 | |
100 mg | In stock | $ 588.00 | |
200 mg | In stock | $ 878.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 114.00 |
Description | (E/Z)-Zotiraciclib inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively. |
Targets&IC50 | JAK2:73 nM, FLT3:56 nM, CDK2:13 nM |
In vitro | (E/Z)-Zotiraciclib has a highly novel kinase inhibitory spectrum inhibiting 17 kinases from a panel of 63, 11 of which are CDK/JAK/FLT family members. Human CYP1A2, 3A4, 2C9, and 2C19 isoforms are not inhibited by (E/Z)-Zotiraciclib at the highest tested concentration of 25 μM, but (E/Z)-Zotiraciclib inhibits CYP2D6 with an IC50 of 0.95 μM, approximately at the plasma Cmax?observed at the maximum tolerated dose. (E/Z)-Zotiraciclib inhibits cell proliferation concentrations in HCT-116 with an IC50 of 0.079 μM and HL-60 with an IC50 of 0.059 μM[1]. (E/Z)-Zotiraciclib is a novel small molecule potent CDK/JAK2/FLT3 inhibitor and mainly metabolized by CYP3A4 and CY1A2 in vitro[2]. |
In vivo | Treatment with (E/Z)-Zotiraciclib (75 mg/kg p.o. q.d. 3×/week) significantly inhibits the growth of tumors with a mean TGI of 82%, while the lower dose(50 mg/kg p.o. 3×/week) is marginally effective. Treatment with (E/Z)-Zotiraciclib using either regime significantly inhibits the growth of tumors with mean TGIs of 42% and 63% for the oral and ip delivery methods, respectively[1]. In pharmacokinetic studies, (E/Z)-Zotiraciclib shows moderate to high systemic clearance (relative to liver blood flow), high volume of distribution (>0.6 L/kg), the oral bioavailability of 24%, ~4 and 37% in mice, rats, and dogs, respectively; and extensive tissue distribution in mice[2]. |
Synonyms | (E/Z)-SB1317, (E/Z)-TG02 |
Molecular Weight | 372.46 |
Formula | C23H24N4O |
CAS No. | 937270-47-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 40mg/mL (107.39mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(E/Z)-Zotiraciclib 937270-47-8 Angiogenesis Cell Cycle/Checkpoint Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors FLT JAK CDK multiple myeloma JAK2 Fms like tyrosine kinase 3 Cyclin dependent kinase FLT3 Janus kinase (E/Z)-SB1317 CD135 leukemias Inhibitor (E/Z)-TG02 CDK2 Cluster of differentiation antigen 135 inhibit cancer (E/Z) Zotiraciclib (E/Z)Zotiraciclib inhibitor